Search
Now showing items 1-1 of 1
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2011)
Background
Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic approaches. The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently ...